Management and Executive

Engineering and Development

Chief Financial Officer

Senior Vice President, Head of Research

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

Kyverna Therapeutics says phase 3 enrollment for Kysa-6 trial to start by year-end

Kyverna to present interim data from Phase 2 portion of KYSA-6 study at AANEM

Cell Therapy Firm Kyverna Advances U.S. Phase 3 MG Trial

Executive Director, Lifecycle Lead

Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. The Lifecycle Lead will manage development programs for drug candidates KYV-101 and KYV-102 by leading cross-functional teams and ensuring alignment with corporate strategy while maximizing the value of the assets.

VP of Human Resources

Sr. Director, Talent Acquisition

Scientific Affairs Lead - Cell Therapy

Sign up with Google

Sign in with Google